I-Mab has released a corporate presentation detailing its progress and strategic initiatives in drug development. Key highlights include the advancement of their bispecific antibodies, givastomig and ragistomig, targeting gastric cancers and refractory/relapsed cancers, respectively. The presentation also outlines the ongoing Phase 1b expansion study for givastomig, which is enrolling ahead of schedule, with topline data expected in the first quarter of 2026. Additionally, I-Mab reports a strong financial position with $168.6 million in cash as of March 31, 2025, projected to support operations through 2027. You can access the full presentation through the link below.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。